A synthetic peptide derived from the B-chain of human relaxin-2, exhibiting potent anti-fibrotic and cardioprotective effects through selective RXFP1 activation.
Alam. Fariha F; Gaspari. Tracey A TA; Kemp-Harper. Barbara K BK; Low. Edward E; Aw. Aaron A; Ferens....
In mice with drug‑induced heart damage, the single‑chain peptide B7‑33 acted like the natural hormone relaxin, cutting heart scarring, inflammation and cell enlargement. It worked as well as relaxin and did these anti‑fibrotic effects faster than the blood‑pressure drug perindopril, which only lowered pressure and didn’t reduce scarring.
Praveen. Praveen P; Wang. Chao C; Handley. Thomas N G TNG; Wu. Hongkang H; Samuel. Chrishan S CS; Ba...
Scientists made a simpler version of the hormone relaxin (called B7-33) that can still activate its receptor, but it disappears from blood very quickly. By attaching a fatty‑acid chain with the right length, they stretched its half‑life in test‑tube serum from about 6 minutes to roughly an hour, without losing activity. The next step is to test this longer‑lasting version in animals.
Bhuiyan. Sadman S; Shen. Matthew M; Chelvaretnam. Sharenya S; Tan. Andre Y AY; Ho. Gideon G; Hossain...
In a mouse model of kidney scarring, the peptide B7-33 (a relaxin‑like drug) helped keep the kidneys from building up too much collagen, a sign of fibrosis. The study also showed a new imaging tool can see these changes without staining tissue.
Marshall. Sarah A SA; O'Sullivan. Kelly K; Ng. Hooi Hooi HH; Bathgate. Ross A D RAD; Parry. Laura J...
In rats, a short peptide called B7-33 acted like the drug serelaxin, helping blood vessels relax better in the gut and stopping damage caused by a pregnancy‑related stress factor, but it didn’t affect other vessels. The study was done in animals and lab dishes, not people, so it’s not a ready‑to‑use supplement yet.
Devarakonda. Teja T; Mauro. Adolfo G AG; Guzman. Geronimo G; Hovsepian. Sahak S; Cain. Chad C; Das....
In mice, a lab-made peptide called B7-33, which mimics part of the natural hormone relaxin, helped protect the heart after a simulated heart attack. It made the damaged area smaller and kept the heart pumping better, likely by helping heart cells survive and reducing stress inside the cells.
In mice, injecting the peptide B7-33 (which activates the brain's relaxin receptor) into the fluid-filled spaces of the brain temporarily reduced pain from inflammation, making the paw less sensitive to touch and heat. The effect lasted about 30 minutes and was blocked for touch pain when a receptor blocker was also given.
Praveen. Praveen P; Kocan. Martina M; Valkovic. Adam A; Bathgate. Ross R; Hossain. Mohammed Akhter M...
Scientists have made a simpler version of the hormone relaxin called B7-33, which is just one chain of the original two-chain molecule. This new peptide can still activate the same receptors in cells and has shown some effects in lab and animal experiments, but no human trials or clear dosing guidelines are provided yet.
Handley. Thomas N G TNG; Praveen. Praveen P; Tailhades. Julien J; Wu. Hongkang H; Bathgate. Ross A D...
Scientists are tweaking a tiny piece of a hormone called relaxin (named B7‑33) to make it more stable and effective at fighting tissue scarring. In lab cells that naturally have the relaxin receptor, B7‑33 works as well as the full hormone, and it has helped reduce organ fibrosis in animal studies. The researchers are now trying chemical tricks (Aib substitution and hydrocarbon stapling) to make the peptide hold its shape better and act stronger.
Hossain. Mohammed Akhter MA; Kocan. Martina M; Yao. Song T ST; Royce. Simon G SG; Nair. Vinojini B V...
Human gene-2 relaxin (H2 relaxin) is a pleiotropic hormone with powerful vasodilatory and anti-fibrotic properties which has led to its clinical evaluation and provisional FDA approval as a treatment for acute heart failure. The diverse effects of H2 relaxin are mediated <i>via</i> its cognate G protein coupled-receptor (GPCR), Relaxin Family Peptide Receptor (RXFP1), leading to stimulation of a combination of cell signalling pathways that includes cyclic adenosine monophosphate (cAMP) and extracellular-signal-regulated kinases (ERK)1/2. However, its complex two-chain (A and B), disulfide-rich insulin-like structure is a limitation to its facile preparation, availability and affordability. Furthermore, its strong activation of cAMP signaling is likely responsible for reported detrimental tumor-promoting actions that may preclude long-term use of this drug for treating human disease. Here we report the design and synthesis of a H2 relaxin B-chain-only analogue, B7-33, which was shown to bind to RXFP1 and preferentially activate the pERK pathway over cAMP in cells that endogenously expressed RXFP1. Thus, B7-33 represents the first functionally selective agonist of the complex GPCR, RXFP1. Importantly, this small peptide agonist prevented or reversed organ fibrosis and dysfunction in three pre-clinical rodent models of heart or lung disease with similar potency to H2 relaxin. The molecular mechanism behind the strong anti-fibrotic actions of B7-33 involved its activation of RXFP1-angiotensin II type 2 receptor heterodimers that induced selective downstream signaling of pERK1/2 and the collagen-degrading enzyme, matrix metalloproteinase (MMP)-2. Furthermore, in contrast to H2 relaxin, B7-33 did not promote prostate tumor growth <i>in vivo</i>. Our results represent the first known example of the minimisation of a two-chain cyclic insulin-like peptide to a single-chain linear peptide that retains potent beneficial agonistic effects.
Milman. N N; Graudal. N N; Nielsen. L S LS; Fenger. K K
The study looked at genetic markers (HLA-A and -B types) in Danish people with a condition called hereditary iron overload (haemochromatosis). It found that certain HLA types, especially A3 and B7, were much more common in patients than in healthy people, suggesting a genetic link, but it does not give any advice on how to treat or prevent the condition.
Barona. P P; Sierrasesúmaga. L L; Antillón. F F; Villa-Elízaga. I I
The study looked at genetic markers (HLA-A and HLA-B types) in a small group of Spanish osteosarcoma patients and found that two specific markers, HLA‑A11 and HLA‑B7, were more common compared to healthy controls. This is a basic cancer‑genetics observation and does not provide any direct advice or actionable steps for health optimization.